Viking Therapeutics (VKTX) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Viking Therapeutics (VKTX) Misses Q2 EPS by 1c

Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update

August 9, 2017 4:05 PM EDT

SAN DIEGO, Aug. 9, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter ended June 30, 2017, and provided an update on its clinical pipeline and other corporate developments.

Highlights from, and Subsequent to, the Quarter Ended June 30, 2017

"We are excited about the progress we've made during the past several months, particularly with respect to our VK5211 and VK2809 programs.  We completed enrollment in our Phase... More